Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Federal Trade Commission
Argus Health
Mallinckrodt
UBS
Baxter

Generated: August 20, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,512,311

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,512,311
Title:Augmentation of intraluminal microvessel formation to facilitate guide wire crossing in chronic total occlusions
Abstract: Method of preparing a clogged animal vessel, e.g. chronic total occlusion of an artery so as to be capable of crossing by a guidewire of an intraluminal device, e.g., angioplasty balloon. The method includes delivering an angiogenic agent to the occlusion site to promote angiogenesis within the occlusion to increases susceptibility to crossing.
Inventor(s): Strauss; Bradley H. (Toronto, CA), Segev; Amit (Raanana, IL)
Assignee:
Application Number:11/606,040
Patent Claims:1. A method of crossing through a chronic total occlusion with a guidewire during a percutaneous coronary intervention, which occlusion cannot be crossed through by a guide wire, the method comprising: (i) delivering an angiogenic agent to the occlusion site to promote angiogenesis within the occlusion; (ii) following step (i), waiting a period of time sufficient to increase susceptibility of the occlusion to crossing with the guidewire through angiogenesis within the occlusion; and (iii) following step (ii), crossing through the occlusion with the guidewire.

2. The method of claim 1, wherein the step of delivering the agent to the occlusion site includes bringing the agent into direct contact with the occlusion.

3. The method of claim 1, wherein delivering the angiogenic agent includes lodging a device within the vessel in the proximity of the occlusion, wherein the device is loaded with the agent and the agent is released therefrom over an extended period of time.

4. The method of claim 1, further comprising delivering a device into the vessel after the step of delivering the agent to retain the agent in direct contact with the occlusion for a period of time.

5. The method of claim 4, wherein the period of time is a predetermined period sufficient to induce angiogenesis in the occlusion.

6. The method of claim 5, wherein the period of time is between one day and ten weeks.

7. The method of claim 5, wherein the period of time is between seven and thirty days.

8. The method of claim 7, wherein the period of time is fourteen and twenty-eight days.

9. The method of claim 1 wherein the vessel is an artery of a human.

10. The method of claim 9, wherein the artery is located in the heart of the human, or the artery is a peripheral artery, or the artery is a femoral artery, or the artery is a popliteal artery, or the artery is a subclavian artery, or the artery is a brachial artery.

11. The method of claim 1, further comprising the step of monitoring the occlusion for the development of microvessels therein, subsequent to the delivery step.

12. The method of claim 11, wherein the monitoring step includes imaging the occlusion using magnetic resonance.

13. The method of claim 1, wherein the angiogenic agent is selected from the group of agents consisting of angiogenic growth factors, pro-angiogenic growth factors, cytokines, combinations of growth factors and/or cytokines, vascular endothelial growth factor, angiopoietin 1, angiopoietin 2, PDGF, FGF-2, TGF-beta, hepatocyte growth factor, TNF-alpha, endothelium-derived nitric oxide, nitric oxide donors, VEGFR-1, VEGFR-2, PDGFR, tie2, hypoxia inducible factor (HIF) 1-alpha, and combinations thereof.

14. The method of claim 13, wherein the angiogenic agent is vascular endothelial growth factor.

15. The method of claim 1, wherein the angiogenic agent is a stem cell that originates from an embryo or bone marrow or circulating blood of adults or endothelial progenitor cells (EPC).

16. The method of claim 15, wherein the angiogenic agent is a bone marrow stem cell.

17. The method of claim 1, further comprising the delivery of a growth factor selected from the group consisting of granulocyte-macrophage colony-stimulating factor, erythropoietin, statin and combinations thereof, so as to mobilize a pro-angiogenic factor into the circulation.

18. The method of claim 1, further comprising inducing overexpression of extracellular matrix components in the occlusion that are pro-angiogenic.

19. The method of claim 1, further comprising delivering a matrix metalloproteinase to the occlusion to enhance angiogenesis in the occlusion.

20. The method of claim 19, wherein the metalloproteinase is collagenase.

21. The method of claim 1, further comprising delivering macrophage colony stimulating factor (M-CSF) to the occlusion.

22. The method of claim 1, further comprising delivering a substance that causes activation of macrophages or chemotaxis of macrophages to the chronic total occlusion to the site of the occlusion.

23. The method according to claim 1, wherein the agent is delivered systemically.

24. The method according to claim 1, wherein the chronic total occlusion is located in a vessel and delivering the angiogenic agent includes inserting a delivery device containing the agent directly into the vessel to percutaneously deliver the agent directly to the site of the occlusion.

25. The method of claim 24, wherein the device includes a catheter, and the step of delivering the agent to the site of the occlusion includes conveying the agent through the catheter.

26. The method of claim 25, wherein the distal end of the catheter is brought within 10 cm of the occlusion prior to conveying the agent to the site through the catheter.

27. The method of claim 24, wherein the agent is delivered through the port of an over-the-wire device for delivering an angioplasty balloon.

28. The method of claim 1, wherein delivering the angiogenic agent includes lodging a device within the vessel in the proximity of the occlusion, wherein the device is loaded with the agent and the agent is released therefrom over an extended period of time of between 20 minutes and 40 minutes.

29. The method of claim 1, wherein delivering the angiogenic agent includes lodging a device within the vessel in the proximity of the occlusion, wherein the device includes a polymer loaded with the agent for release therefrom in use.

Details for Patent 8,512,311

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04 ➤ Sign Up 2024-12-02 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
AstraZeneca
Federal Trade Commission
Farmers Insurance
Johnson and Johnson
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.